CalyxoPRIVATE · FOUNDED 2016Each bar is the last disclosed mark — $684.6M for Calyxo (basis undisclosed, Apr 2026) and $200M for Kriya Therapeutics (basis undisclosed, Jan 2021).
CalyxoPRIVATEHealth · US · 2016The $684.6M tells you…At least one valuation basis is undisclosed, so the two numbers stay side by side, each with its own chip, and no ratio is scored. Both are private: there is no public quote and no Canborsa market on either name.
Calyxo operates in Medical Devices, and Kriya Therapeutics operates in Gene therapy and biotech.
Calyxo is valued at $684.6M, and Kriya Therapeutics at $200M.
Calyxo has raised $122.7M across 3 rounds, and Kriya Therapeutics has raised $770.5M across 4 rounds.
Calyxo's most recent round was Series F, raising $40M in April 2026; Kriya Therapeutics' was Series C, raising $270M in May 2022.
Calyxo employs around 20 people; Kriya Therapeutics employs around 197.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
